
Director of Cyber Threat Intelligence (CTI)
AstraZeneca
Summary
The Director of Cyber Threat Intelligence will lead a highly technical CTI function within AstraZeneca's Cybersecurity Operations division, managing a team of analysts to deliver strategic, operational, and tactical intelligence that measurably reduces risk across the enterprise, including manufacturing, clinical trial platforms, and R&D environments. This role anchors CTI to 'intel-to-action' outcomes, partnering closely with Vulnerability Management, Detection Engineering, and Incident Response to harden controls, prioritize patching, improve detections, and accelerate response.
Job description
Key Responsibilities
- Program Leadership and Strategy: Define CTI vision, operating model, and roadmap aligned to AstraZeneca's cyber risk reduction strategy, with special emphasis on manufacturing continuity, clinical data integrity, and R&D IP protection.
- Adversary Prioritization Framework: Design and operate a scoring rubric that ranks actors based on intent/capability/relevance, TTP emergence and prevalence, organization-specific exposure to known vulnerabilities/CVEs, and global 'viral' events, maintaining dynamic watchlists and escalation triggers.
- MTTI Metric and Analytics: Implement analytic methods to estimate mean time-to-impact per adversary using internal telemetry, historical incidents, industry reporting, and confidence levels, performing comparisons with IR's MTTC to drive control improvements.
- Attack Path Modeling: Build and maintain end-to-end attack path models from initial access to material impact across IT-to-OT pivots, clinical platforms, and R&D environments, mapping steps to MITRE ATT&CK (Enterprise/ICS), identify control gaps and choke points, derive detections-as-code and hunt hypotheses, and support validation efforts including purple-team exercises and adversary emulation.
- Dark Web and Closed-Source Monitoring: Establish collection and monitoring across dark web forums, marketplaces, breach dumps, and closed channels to identify emerging TTPs, credential leaks, data exposure, access-broker listings, and targeting of manufacturing, clinical, or R&D assets, integrating validated findings into TIP/SIEM pipelines, trigger takedown requests where feasible, and deliver rapid advisories with confidence ratings and specific actions.
- Third-Party and Ecosystem Intelligence: Deliver risk insights for CROs/CMOs/logistics/technology vendors, monitor credential leakage and domain spoofing, and support/coordinate takedown operations when needed.
- Structured Threat Actor Attribution (Diamond Model): Lead disciplined attribution using the Diamond Model and complementary frameworks, correlating TTPs, tooling lineage, code-reuse, infrastructure overlaps, and victimology with confidence levels and analytic caveats, documenting hypotheses, alternative explanations, and disconfirming evidence, and producing reusable actor profiles and pivot paths.
- Support Vulnerability Management: Partner with Vulnerability Management to contextualize CVEs and deliver risk-based patching prioritization across AstraZeneca's estate including IT/OT, clinical platforms, and lab environments.
- Support Detection Engineering: Develop detection use cases to feed our detection-as-code pipeline and support detection ATT&CK coverage mapping, content tuning, and false-positive reduction.
- Support GSOC/Incident Response: Provide real-time adversary context that is highly technical including kill-chain reconstruction, containment recommendations, and countermeasures, producing post-incident intelligence retrospectives and detection/architecture improvements.
- Operational and Executive Reporting: Produce daily threat intelligence highlights, threat actor/campaign profiles, quarterly threat briefings, and other ad hoc intelligence products, ensuring products include quantified risk narratives for senior leadership.
- Tooling and Automation: Optimize integrations across TIP, SIEM, EDR, case management, and telemetry; manage indicator lifecycle, automate enrichment, and measure source fidelity/bias.
- External Engagement: Lead participation with sector bodies (e.g., H-ISAC), peer sharing groups, and government/industry partners; track and assess global events and rapidly translate into actionable enterprise guidance.
- Team Leadership and Development: Recruit, mentor, and grow a diverse team of CTI analysts; build career paths, training plans, and knowledge-sharing practices; foster a culture of technical excellence and clear, actionable communication.
Minimum Qualifications
- Leadership and Strategic Impact: 10+ years in cyber threat intelligence, detection engineering, incident response, or related domains; 5+ years leading technical CTI teams in global enterprises.
- Demonstrated ability to set vision, influence strategy, and deliver outcomes tied to enterprise risk reduction.
- Decision Making and Accountability: Proven ownership of adversary-centric CTI programs that directly drive vulnerability prioritization, detections-as-code, hunts, and incident response.
- Technical Depth (ATT&CK Enterprise/ICS): Deep expertise mapping TTPs to MITRE ATT&CK, defining coverage strategies, and translating gaps into high-fidelity detections and hunt hypotheses; skilled in industrial/OT contexts.
- Attack Path Modeling and Risk Translation: Hands-on delivery of end-to-end attack paths across IT-to-OT pivots, clinical platforms, and R&D environments; validation via purple-team/adversary emulation.
- Adversary Prioritization and Scoring: Designed and operated tailored actor scoring incorporating intent/capability, TTP emergence/prevalence, org exposure to CVEs, and global/viral events.
- Structured Attribution Tradecraft: Applied the Diamond Model and complementary frameworks with documented hypotheses, caveats, disconfirming evidence, and confidence statements.
- Metrication (MTTI vs. MTTC): Built mean time-to-impact metrics per actor and operationalized comparisons to IR's mean time-to-containment.
- Vulnerability Intelligence for Hardening: Delivered contextual CVE analysis and risk-based patch recommendations across IT, OT/ICS, clinical, and lab environments.
- Detection Engineering Collaboration: Co-developed detections-as-code (e.g., Sigma, KQL, SPL), tuned content to reduce false positives, and closed ATT&CK coverage gaps.
- Incident Intelligence Support: Provided real-time adversary context, kill-chain reconstruction, containment recommendations, and post-incident retrospectives.
- Collection, Tooling, and Automation: Operated dark web/closed-source monitoring; integrated findings into TIP/SIEM/EDR pipelines; managed indicator lifecycle, automated enrichment, and measured source fidelity/bias.
- Stakeholder Partnership and Communication: Clear, concise communication of complex technical intelligence to executives and cross-functional partners; ability to influence without authority.
- Education: Bachelor's degree in a relevant field (Computer Science, Information Security, Intelligence Studies, or equivalent experience).
Preferred Qualifications
- Sector Experience and Regulatory Context: Experience in pharmaceuticals, life sciences, healthcare, or manufacturing; familiarity with GMP/CSV, clinical data obligations, and R&D IP protection.
- OT/ICS and Critical Operations: Hands-on work with MES, SCADA, PLC ecosystems; ATT&CK for ICS usage; understanding of OT-safe response practices.
- Clinical/R&D Platforms: Exposure to CTMS, EDC, IRT, ELN, LIMS, HPC, and data lake environments.
- Program Metrics and Outcomes: Built dashboards tracking MTTI by actor, ATT&CK coverage indices, intel-informed patch SLAs, hunter ROI, and executive risk narratives.
- Advanced Tooling/Automation: TIP administration, SIEM/EDR content engineering, enrichment/orchestration pipelines, case management integration, and indicator lifecycle automation.
- Threat Modeling and Quantification: Ability to translate attack paths into quantified risk scenarios and prioritized control investments.
- External Partnerships: Active engagement with H-ISAC/ISAOs and government/industry partners.
- Certifications: One or more of GCTI, GREM, GRID, GCIH, CISSP, or equivalent demonstrated expertise.
- People Leadership: Built diverse, high-performing teams; established career paths, coaching frameworks, and a culture of analytic rigor.
Requirements
- 10+ years in cyber threat intelligence, detection engineering, incident response, or related domains
- 5+ years leading technical CTI teams in global enterprises
- Demonstrated ability to set vision, influence strategy, and deliver outcomes tied to enterprise risk reduction
- Proven ownership of adversary-centric CTI programs
- Deep expertise mapping TTPs to MITRE ATT&CK
- Hands-on delivery of end-to-end attack paths across IT-to-OT pivots
- Designed and operated tailored actor scoring
- Applied the Diamond Model and complementary frameworks
- Built mean time-to-impact metrics per actor
- Delivered contextual CVE analysis and risk-based patch recommendations
- Co-developed detections-as-code (e.g., Sigma, KQL, SPL)
- Provided real-time adversary context, kill-chain reconstruction, containment recommendations
- Operated dark web/closed-source monitoring
- Clear, concise communication of complex technical intelligence to executives
- Bachelor's degree in a relevant field (Computer Science, Information Security, Intelligence Studies, or equivalent experience)
Benefits
- Retirement programs
- Paid time off
- Health coverage
- Dental coverage
- Vision coverage
- Short-term incentive bonuses
- Equity-based awards
Company overview
AstraZeneca is a global, science-led, patient-focused pharmaceutical company dedicated to accelerating the delivery of life-changing medicines that create enduring value for patients, society, and shareholders. With a workforce of over 94,300 employees worldwide, the company operates across three core therapy areas: Oncology, BioPharmaceuticals (including Cardiovascular, Renal & Metabolism, Respiratory & Immunology), and Rare Disease. Headquartered in Cambridge, UK, AstraZeneca maintains strategic R&D centers in Cambridge, Gaithersburg (US), Boston (US), Gothenburg (Sweden), Shanghai, and Beijing. The company generated $54.1 billion in total revenue in 2024 and invested $13.6 billion in scientific research and development. AstraZeneca's bold aspiration is to be pioneers in science, lead in disease areas, and transform patient outcomes, with a goal to launch 20 new medicines and achieve $80 billion in total revenue by 2030. The company is recognized for its commitment to sustainability, health equity, and creating an inclusive work environment where diverse perspectives drive innovation.